DexCom, Inc. (DXCM) Stock Analysis

DexCom’s primary competitive advantages are rooted in technology leadership, ecosystem integration, and high switching costs. The company’s G7 and G7 15-Day sensors are recognized for best-in-class accuracy (MARD of 8.0%), real-time alerts, and seamless integration with leading automated insulin delivery (AID) systems such as Tandem and Insulet. This integration is a key differentiator versus Abbott’s FreeStyle Libre, which, while lower cost and dominant in unit share (48.5% US CGM share in 2025 vs. DexCom’s 44.7%), is less entrenched in the intensive insulin segment where device interoperability and reliability are critical.

DexCom’s recurring revenue model, driven by disposable sensors, is reinforced by high user retention—especially among Type 1 and intensive insulin users—due to the complexity and risk of switching systems. The company’s Clarity and Share/Follow platforms further embed users and caregivers, creating network effects and data stickiness.

Barriers to entry are substantial: regulatory approval, manufacturing scale, and payer coverage require years of investment. DexCom’s clinical evidence and physician trust support premium pricing and broad reimbursement, particularly in the US. However, pricing pressure from Abbott and expansion into lower-acuity, price-sensitive segments (e.g., Type 2 non-insulin) represent ongoing threats. DexCom’s response—launching Stelo and scaling manufacturing—aims to defend share and margins as the market broadens.